photo_2022-08-05_18-30-52

PFIZER M&A ACCELERATING IN TALKS TO BUY GLOBAL BLOOD THERAPEUTICS FOR ~$5BILLION Buying the company would add to Pfizer’s presence in rare diseases, furnishing a drug already on sale for the treatment of sickle-cell disease as well as 2 in development that have produced positive results in preliminary studies. Pfizer has been interested in sickle cell, but a drug it had been developing failed in 2019. It has another one in early-stage development. The New York-based drugmaker plans to add $25 billion in revenue from business-development moves like M&A by 2030. Flush with the cash its "pandemic products" have generated, Pfizer has been inking deals left and right. In May, it agreed to buy the rest of migraine drugmaker Biohaven Pharmaceutical Holding Co. for $11.6 billion. Earlier, Pfizer had bought Arena Pharmaceuticals for $6.7 billion and said it would acquire privately held respiratory virus drugmaker Reviral Ltd. Article https://www.wsj.com/articles/pfizer-in-advanced-talks-to-buy-global-blood-therapeutics-for-about-5-billion-11659713670